摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-氯-4-甲砜基苯胺 | 23153-12-0

中文名称
3-氯-4-甲砜基苯胺
中文别名
3-氯-4-甲基磺酰基苯胺
英文名称
3-chloro-4-(methylsulfonyl)aniline
英文别名
3-Chloro-4-methanesulfonyl-phenylamine;3-chloro-4-methylsulfonylaniline;3-Chlor-4-methylsulfonyl-anilin
3-氯-4-甲砜基苯胺化学式
CAS
23153-12-0
化学式
C7H8ClNO2S
mdl
MFCD08692449
分子量
205.665
InChiKey
VBEZMRJLMPYKBT-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    170-171
  • 沸点:
    423.0±45.0 °C(Predicted)
  • 密度:
    1.414±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    0.9
  • 重原子数:
    12
  • 可旋转键数:
    1
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.142
  • 拓扑面积:
    68.5
  • 氢给体数:
    1
  • 氢受体数:
    3

安全信息

  • 危险等级:
    IRRITANT
  • 危险品标志:
    Xi
  • 海关编码:
    2921420090
  • 危险性防范说明:
    P261,P305+P351+P338
  • 危险性描述:
    H315,H319,H335
  • 储存条件:
    室温且干燥环境下使用。

SDS

SDS:2fd956cebeb1f3a2d37234a3fa762af8
查看
Material Safety Data Sheet

Section 1. Identification of the substance
Product Name: 3-Chloro-4-methylsulfonylaniline
Synonyms:

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

Section 3. Composition/information on ingredients.
Ingredient name: 3-Chloro-4-methylsulfonylaniline
CAS number: 23153-12-0

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C7H8ClNO2S
Molecular weight: 205.7

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen chloride, sulfur oxides.

Section 11. Toxicological information
No data.

Section 12. Ecological information
No data.

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

Section 14. Transportation information
Non-harzardous for air and ground transportation.

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.


SECTION 16 - ADDITIONAL INFORMATION
N/A

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    3-氯-4-甲砜基苯胺calcium carbonate 作用下, 以 甲醇二氯甲烷 为溶剂, 20.0 ℃ 、101.33 kPa 条件下, 反应 1.0h, 生成 (Z)-methyl N-(3-chloro-4-(methylsulfonyl)phenyl)-N'-cyanocarbamimidothioate
    参考文献:
    名称:
    [EN] TRIAZOLE COMPOUNDS AS ANTIVIRALS
    [FR] COMPOSÉS TRIAZOLES EN TANT QU'ANTIVIRAUX
    摘要:
    本发明公开了公式I的化合物:其中公式I中的变量定义如本文所述。还公开了包含此类化合物的药物组合物以及使用公式I化合物预防或治疗HCV感染的方法。
    公开号:
    WO2014006066A1
  • 作为产物:
    描述:
    3-氯-4-氟硝基苯 氢气间氯过氧苯甲酸 作用下, 以 甲醇二氯甲烷N,N-二甲基甲酰胺 为溶剂, 25.0~90.0 ℃ 、34.48 kPa 条件下, 反应 27.0h, 生成 3-氯-4-甲砜基苯胺
    参考文献:
    名称:
    1,2-二芳基吡咯作为环加氧酶-2的有效和选择性抑制剂。
    摘要:
    已经合成了一系列的1,2-二芳基吡咯,并发现它们含有非常有效的人环氧化酶-2(COX-2)酶抑制剂。本文介绍了利用Paal-Knorr反应合成靶分子的简短实用方法。1上的亲电子取代以区域选择性方式进行,该方法用于生成许多四取代的吡咯。通过修饰芳基环和吡咯环中的取代基,研究了该系列的详细比吸收率。二芳基吡咯1是非常有效的(COX-2,IC50 = 60 nm)和选择性(COX-1 / COX-2 => 1700)抑制剂,而异构体2对COX-2则完全无活性。对氟苯环上的取代基进行1的修饰可产生非常有效的COX-2抑制剂(IC50 = 40-80 nm),且具有出色的选择性(1200至> 2500)与COX-1。含有磺酰胺基的类似物20是出色的COX-2抑制剂,IC50为14 nm。在吡咯环的3位上含有COCF3,SO2CF3或CH2OAr等基团的四取代吡咯可提供出色的抑制剂(COX-2,IC50
    DOI:
    10.1021/jm970036a
点击查看最新优质反应信息

文献信息

  • DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND
    申请人:Shimada Itsuro
    公开号:US20120040968A1
    公开(公告)日:2012-02-16
    Provided is a compound useful as an inhibitor against the kinase activity of EML4-ALK fusion protein. As a result of intensive and extensive studies on compounds having inhibitory activity against the kinase activity of EML4-ALK fusion protein, the present inventors found that the diamino heterocyclic carboxamide compounds of the present invention had inhibitory activity against the kinase activity of EML4-ALK fusion protein. By this finding, the present invention was completed. The compounds of the present invention can be used as a pharmaceutical composition for preventing and/or treating cancer, such as lung cancer, non-small cell lung cancer, and small cell lung cancer.
    提供的是一种化合物,可作为抑制EML4-ALK融合蛋白激酶活性的抑制剂。通过对具有抑制EML4-ALK融合蛋白激酶活性的化合物进行深入广泛的研究,本发明人发现本发明的二氨基杂环羧酰胺化合物对EML4-ALK融合蛋白激酶活性具有抑制作用。通过这一发现,完成了本发明。本发明的化合物可用作预防和/或治疗癌症,如肺癌、非小细胞肺癌和小细胞肺癌的药物组合物。
  • [EN] 1-PHENYLPYRROLE COMPOUNDS<br/>[FR] 1-PHÉNYLPYRROLES
    申请人:EXELIXIS INC
    公开号:WO2010042626A1
    公开(公告)日:2010-04-15
    The present invention comprises a compound for the prevention and/or treatment of cardiovascular diseases, nephropathy, fibrosis, primary aldosteronism or edema. The compound is of the following general formula (I): wherein R1 represents a C1 -C3 alkyl group; R2 represents a hydroxy -C1 -C4 alkyl group and the like; R3 represents a halogeno group, a halogeno-C1 -C3 alkyl group and the like; R4 represents a hydrogen atom, a halogeno group and the like,- R5 represents a sulfamoyl group or a C1-C3 alkylsulf onyl group; R6 represents a hydrogen atom, a halogeno group and the like] or an N-oxide, atropisomer of the foregoing, or pharmaceutically acceptable salt of the foregoing.
    本发明涉及一种用于预防和/或治疗心血管疾病、肾病、纤维化、原发性醛固酮分泌亢进或水肿的化合物。该化合物具有以下一般式(I):其中R1代表C1-C3烷基基团;R2代表一个羟基-C1-C4烷基基团等;R3代表一个卤素基团,一个卤素-C1-C3烷基基团等;R4代表一个氢原子,一个卤素基团等;R5代表一个磺胺基团或一个C1-C3烷基磺酰基团;R6代表一个氢原子,一个卤素基团等,或者上述化合物的N-氧化物、旋光异构体或上述化合物的药用可接受的盐。
  • Model studies on a synthetically facile series of N-substituted phenyl-N′-pyridin-3-yl ureas leading to 1-(3-pyridylcarbamoyl) indolines that are potent and selective 5-HT2C/2B receptor antagonists
    作者:Steven M. Bromidge、Steven Dabbs、David T. Davies、Susannah Davies、D.Malcolm Duckworth、Ian T. Forbes、Angela Gadre、Peter Ham、Graham E. Jones、Frank D. King、Damian V. Saunders、Kevin M. Thewlis、Deepa Vyas、Thomas P. Blackburn、Vicky Holland、Guy A. Kennett、Graham J. Riley、Martyn D. Wood
    DOI:10.1016/s0968-0896(99)00228-x
    日期:1999.12
    antagonists have been prepared by rapid parallel synthesis. These N-substituted phenyl-N'-pyridin-3-yl ureas were found to have a range of 5-HT2C receptor affinities and selectivities over the closely related 5-HT2A receptor. Extrapolation of simple SAR, derived from this set of compounds, to the more active but synthetically more complex 1-(3-pyridylcarbamoyl)indoline series allowed us to target optimal
    已经通过快速平行合成制备了一系列的5-HT 2C拮抗剂模型。发现这些N-取代的苯基-N'-吡啶-3-基脲比密切相关的5-HT2A受体具有一系列的5-HT2C受体亲和力和选择性。从这组化合物中衍生出的简单SAR外推至活性更高但合成上更复杂的1-(3-吡啶基氨基甲酰基)二氢吲哚系列,使我们能够靶向最佳取代模式并鉴定有效和选择性的5-HT(2C / 2B)拮抗剂。
  • [EN] SUBSTITUTED PIPERIDINE DERIVATIVES AND METHODS FOR PREPARING THE SAME<br/>[FR] DÉRIVÉS DE PIPÉRIDINE SUBSTITUÉE ET PROCÉDÉS POUR LES PRÉPARER
    申请人:HYUNDAI PHARM CO LTD
    公开号:WO2013105753A1
    公开(公告)日:2013-07-18
    The present invention relates to a novel compound or a pharmaceutically acceptable salt thereof, a preparation method thereof and a pharmaceutical composition for treating metabolism-related disorder containing the same. Specifically, the present invention relates to a compound of the formula 1, which can activate GPR119 to treat metabolism-related disorders, including diabetes and related diseases, diabetes-related microvascular complications, diabetes-related macrovascular complications, cardiovascular abnormalities, metabolic syndrome and its constituent diseases, and obesity.
    本发明涉及一种新颖化合物或其药用可接受盐,以及其制备方法和含有该化合物的用于治疗与代谢相关疾病的药物组合物。具体而言,本发明涉及一种符合式1的化合物,可以激活GPR119以治疗与代谢相关的疾病,包括糖尿病及相关疾病、糖尿病相关微血管并发症、糖尿病相关大血管并发症、心血管异常、代谢综合征及其组成疾病以及肥胖症。
  • Pyrrole Derivatives As Pharmaceutical Agents
    申请人:Canne Bannen Lynne
    公开号:US20080234270A1
    公开(公告)日:2008-09-25
    Compounds, compositions and methods for modulating the activity of receptors are provided. In particular compounds and compositions are provided for modulating the activity of receptors and for the treatment, prevention, or amelioration of one or more symptoms of disease or disorder directly or indirectly related to the activity of the receptors.
    提供了用于调节受体活性的化合物、组合物和方法。特别提供了用于调节受体活性的化合物和组合物,以及用于治疗、预防或改善与受体活性直接或间接相关的一种或多种疾病或紊乱的症状的方法。
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫 龙胆紫 齐达帕胺 齐诺康唑 齐洛呋胺 齐墩果-12-烯[2,3-c][1,2,5]恶二唑-28-酸苯甲酯 齐培丙醇 齐咪苯 齐仑太尔 黑染料 黄酮,5-氨基-6-羟基-(5CI) 黄酮,6-氨基-3-羟基-(6CI) 黄蜡,合成物 黄草灵钾盐